| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 12/18/2008 | US20080311113 Method for treating adamts-5-associated disease |
| 12/18/2008 | US20080311109 Nucleotide sequences coding tumor polypeptides for use in diagnosis, prevention and treatment of cell proliferative disorders |
| 12/18/2008 | US20080311092 Murine Stem Cells and Applications Thereof |
| 12/18/2008 | US20080311090 Methods for inhibition of proliferative disease, including hepatocellular carcinoma |
| 12/18/2008 | US20080311084 Mapc Engraftment in the Hematopoietic System |
| 12/18/2008 | US20080311080 Bifidobacterium in the treatment of inflammatory disease |
| 12/18/2008 | US20080311039 Therapeutic and Prognostic Factor Yy1 in Human Cancer |
| 12/18/2008 | US20080311037 Compounds which bind PSMA and uses thereof |
| 12/18/2008 | CA2727528A1 Heme-oxygenase inhibitors and use of the same in the treatment of cancer and diseases of the central nervous system |
| 12/18/2008 | CA2694860A1 Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer |
| 12/18/2008 | CA2692922A1 Azaindole-indole coupled derivatives, preparation methods and uses thereof |
| 12/18/2008 | CA2692050A1 Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase |
| 12/18/2008 | CA2690771A1 Injectable polymer-lipid blend for localized drug delivery |
| 12/18/2008 | CA2690569A1 Indolinone derivatives and their use in treating disease-states such as cancer |
| 12/18/2008 | CA2690567A1 New compounds |
| 12/18/2008 | CA2690345A1 .beta.gbp, compositions comprising .beta.gbp, and related methods and uses thereof |
| 12/18/2008 | CA2689974A1 Mir-34 regulated genes and pathways as targets for therapeutic intervention |
| 12/18/2008 | CA2689079A1 Equol-containing extract, method for production thereof, method for extraction of equol, and equol-containing food |
| 12/18/2008 | CA2688472A1 Biphenylcarboxamide derivatives as hedgehog pathway modulators |
| 12/18/2008 | CA2687746A1 Methods of treating, diagnosing and detecting fgf21-associated disorders |
| 12/17/2008 | EP2003211A2 Process for producing optically active (s)-7-hydroxy-6-methylheptane-2-one and precursor thereof |
| 12/17/2008 | EP2003207A2 Antisense inhibition of PTP1B expression |
| 12/17/2008 | EP2003201A2 Compounds and methods for therapy and diagnosis of lung cancer |
| 12/17/2008 | EP2003140A2 Galactose derivative, drug carrier and medicinal composition |
| 12/17/2008 | EP2003130A2 Novel pyridine derivative having anti-helicobacter pylori activity |
| 12/17/2008 | EP2002840A2 Method for treating oncological diseases |
| 12/17/2008 | EP2002839A1 Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
| 12/17/2008 | EP2002837A1 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| 12/17/2008 | EP2002836A1 Cyclocondensed azaindoles active as kinase inhibitors |
| 12/17/2008 | EP2002835A1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| 12/17/2008 | EP2002834A1 Aryl and hetaryl amides as modulators of EP2 receptors |
| 12/17/2008 | EP2002832A2 Composition containing lignan compound |
| 12/17/2008 | EP2001894A1 Novel bis-2-difluoro-pyrroloý2,1-c¨ý1,4¨benzodiazepine dimmers |
| 12/17/2008 | EP2001882A1 Substituted indazole derivatives, their manufacture and use as pharmaceutical agents |
| 12/17/2008 | EP2001880A2 Heterobicyclic pyrazole compounds and methods of use |
| 12/17/2008 | EP2001868A1 Inhibitors of the interaction between mdm2 and p53 |
| 12/17/2008 | EP2001864A1 Heterocyclic organic compounds for the treatment of in particular melanoma |
| 12/17/2008 | EP2001857A2 Photoactive compounds and compositions and uses thereof |
| 12/17/2008 | EP2001856A1 Crystalline forms of n- {2-tert -butyl -1- [ (4,4- dif luorocyclohexyl) methyl]-lh-benzimidazol-5- yl}ethanesulfonamide salts |
| 12/17/2008 | EP2001505A2 Cathepsin propeptide and uses thereof |
| 12/17/2008 | EP2001502A1 Parenteral low dose type 1 interferons for bladder cancer |
| 12/17/2008 | EP2001492A1 A method of treating cancer and/or cellular proliferative conditions and agents targeting hyaluronan anabolism useful for same |
| 12/17/2008 | EP2001488A2 Prevention and treatment of cancer and other diseases |
| 12/17/2008 | EP2001480A2 Indazole compounds |
| 12/17/2008 | EP2001477A2 Paclitaxel combination |
| 12/17/2008 | EP2001441A2 Cancer treatments |
| 12/17/2008 | EP1603919B1 7-imino derivatives of camptothecin having antitumor activity |
| 12/17/2008 | EP1572695B1 Porphyrin derivatives, methods for obtaining same, and use thereof in radioimmunotherapy |
| 12/17/2008 | EP1536778B1 Proteins binding to cross-beta structure comprising amyloid and methods for modulation of the cross-beta structure, its formation and its associated toxicity |
| 12/17/2008 | EP1443046B1 Novel 4-(2furoyl)aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same |
| 12/17/2008 | EP1333865B1 Inorganic low density radionuclide coated particles |
| 12/17/2008 | EP1322654B1 Platinum complexes as antitumour agents |
| 12/17/2008 | EP1282609B1 Piperazinedione compounds |
| 12/17/2008 | EP1230214B1 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 12/17/2008 | EP1198458B1 Ceramide analogs, process for their preparation and their use as antitumor agents |
| 12/17/2008 | EP1077943B1 Heterocyclic inhibitors of p38 |
| 12/17/2008 | EP1007696B1 Il-13 receptor specific chimeric proteins and uses thereof |
| 12/17/2008 | EP0791067B1 Protein kinase npk-110 |
| 12/17/2008 | CN101326197A Human monoclonal antibodies to O8E |
| 12/17/2008 | CN101326191A Phosphine transition metal complex, method for producing same and antitumor agent containing same |
| 12/17/2008 | CN101326186A Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors |
| 12/17/2008 | CN101326182A 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors |
| 12/17/2008 | CN101326175A Polymorphs of a C-MET/HGFR inhibitor |
| 12/17/2008 | CN101326170A Novel macrolide compounds with antibiotic and antneoplastic properties |
| 12/17/2008 | CN101326164A Inhibitors of CCR9 activity |
| 12/17/2008 | CN101325968A Anti-CTLA-4 antibody compositions |
| 12/17/2008 | CN101325958A Crystalline lestaurtinib hydrates and crystalline lestaurtinib hemihydrate hemiacetonitrileate and crystalline lestaurtinib hemihydrate hemitetrahydrofuranate |
| 12/17/2008 | CN101325953A 4-heteroaryl-pyrimidine derivatives and use thereof as protein kinase inhibitors |
| 12/17/2008 | CN101323649A Method for extracting mushroom polysaccharide by using ultra-high pressure |
| 12/17/2008 | CN101323648A Extraction method and and purification method of Sanghuang mushroom polysaccharide |
| 12/17/2008 | CN101323646A Phellinus polysaccharide II having antineoplastic activity, extraction and separation method thereof |
| 12/17/2008 | CN101323643A Optimized TACI-Fc fuse protein |
| 12/17/2008 | CN101323634A Induced nuclear receptor TR3 expressed cardiac glycoside compounds and use thereof |
| 12/17/2008 | CN101323631A Phosphine transition-metal coordination compound having ferrocene frame having ferrocene frame, manufacturing method thereof and carcinostatic agent |
| 12/17/2008 | CN101323629A 4-{6-[5-(2-chlorinde-6- methylaniline formyl)-thiazole-2-amido]-2-methyl pyrimidine-4}-piperazine-1- diethyl methylphosphate |
| 12/17/2008 | CN101323606A Extraction and purification method of sesquiterpenes coumarin ether and use thereof |
| 12/17/2008 | CN101323591A 5- or 6-substited naphthoyl imines compounds and antineoplastic application |
| 12/17/2008 | CN101323569A Sesquiterpenes southernwood terpene ester AE, and extraction and purification method thereof |
| 12/17/2008 | CN101322849A Radioactive sustained-release particle and preparation and use thereof |
| 12/17/2008 | CN101322845A Erianin inclusion compound |
| 12/17/2008 | CN101322842A Recombinant Staphylococcus aureus enterotoxin G oral preparation and use |
| 12/17/2008 | CN101322841A Recombinant Staphylococcus aureus enterotoxin J oral preparation and use |
| 12/17/2008 | CN101322832A Quick acting liquid medicine specific for benign tumor or malignant tumor transferred from disease in five viscera and six bowels |
| 12/17/2008 | CN101322825A Medicament composition for treating malignant tumour |
| 12/17/2008 | CN101322820A Chinese medicine compound composition for treating gynecology hysteromyoma and pelvic inflammation mass |
| 12/17/2008 | CN101322817A Compound flavescent sophora root sustained-release dropping pill and preparation thereof |
| 12/17/2008 | CN101322804A Chinese medicine for treating liver cancer and stomach cancer |
| 12/17/2008 | CN101322793A Special cure for cancer lesion |
| 12/17/2008 | CN101322766A Spray for treating cervical cancer using termite as principal raw material |
| 12/17/2008 | CN101322740A Chinese medicinal composition for resisting tumor and assisting chemoradiotherapy of tumour |
| 12/17/2008 | CN101322737A Persimmon leaf flavones extract and preparation thereof |
| 12/17/2008 | CN101322723A Toad venom extract and preparation thereof |
| 12/17/2008 | CN101322720A Arsenic trioxide emulsion for intravenous injection and preparation thereof |
| 12/17/2008 | CN101322719A Arsenic trioxide solid lipid nano granule, formulation and preparation thereof |
| 12/17/2008 | CN101322707A Pharmaceutical composition containing histone deacetylase inhibitor |
| 12/17/2008 | CN101322700A Applications of naringenin and naringin as signal pathway inhibitor of transforming growth factor-beta 1 |
| 12/17/2008 | CN101322699A Preparation of docetaxel liposome and freeze-dried powder injection thereof |
| 12/17/2008 | CN101322689A Preparation of docetaxel long-circulating liposome and freeze-dried powder injection thereof |
| 12/17/2008 | CN101322681A Method for preparing nano micelle formulation of anthracene nucleus antineoplastic antibiotic |
| 12/17/2008 | CN101322514A Green tea Ganoderma lucidum drink and preparation method thereof |